Reply

Janske Reiling, Nick Butler, Andrew H. Simpson, Peter Hodgkinson, Catherine Campbell, David Lockwood, Kim J. Bridle, Nishreen Santrampurwala, Laurence J. Britton, Darrell H. Crawford, Cornelius H.C. Dejong, Jonathan Fawcett – 19 April 2021

Pharmacological Activation of Nrf2 Enhances Functional Liver Regeneration

Benjamin K.Y. Chan, Mohamed Elmasry, Shiva S. Forootan, Giusy Russomanno, Tobias M. Bunday, Fang Zhang, Nathalie Brillant, Philip J. Starkey Lewis, Rhona Aird, Emanuele Ricci, Timothy D. Andrews, Rowena L. Sison‐Young, Amy L. Schofield, Yongxiang Fang, Adam Lister, Jack W. Sharkey, Harish Poptani, Neil R. Kitteringham, Stuart J. Forbes, Hassan Z. Malik, Stephen W. Fenwick, B. Kevin Park, Christopher E. Goldring, Ian M. Copple – 18 April 2021

Applying Administrative Data‐Based Coding Algorithms for Frailty in Patients With Cirrhosis

Jeremy Louissaint, Susan L. Murphy, Christopher J. Sonnenday, Anna S. Lok, Elliot B. Tapper – 18 April 2021 – Frailty is a powerful prognostic tool in cirrhosis. Claims‐based frailty scores estimate the presence of frailty without the need for in‐person evaluation. These algorithms have not been validated in cirrhosis. Whether they measure true frailty or perform as well as frailty in outcome prediction is unknown.

Efficacy and Safety of Endoscopic Balloon Placement for Weight Loss in Patients With Cirrhosis Awaiting Liver Transplantation

Kymberly D. Watt, Julie K. Heimbach, Monika Rizk, Pete Jaruvongvanich, William Sanchez, John Port, Sudhakar K. Venkatesh, Heather Bamlet, Kathryn Tiedtke, Harmeet Malhi, Andres Acosta Cardenas, Karen Grothe, Matthew Clark, Manpreet S. Mundi, Barham K. Abu Dayyeh – 17 April 2021 – The efficacy and safety of a fluid‐filled intragastric balloon (IGB) for weight loss in patients with cirrhosis on the liver transplantation (LT) waiting list is unknown.

Occult Hepatocellular Carcinoma Associated With Transjugular Intrahepatic Portosystemic Shunts in Liver Transplant Recipients

Lauren N. Krumeich, Jenna Mancinelli, Andy Cucchiara, Kevin Eddinger, David Aufhauser, Drew W. Goldberg, Evan S. Siegelman, Mark Rosen, K. Rajender Reddy, Maarouf Hoteit, Emma E. Furth, Kim M. Olthoff, Abraham Shaked, Matthew Levine, Peter Abt – 13 April 2021 – Transplant eligibility for hepatocellular carcinoma (HCC) is determined by the imaging identification of tumor burden within the Milan criteria. Transjugular intrahepatic portosystemic shunt(s) (TIPS) reduce portal hypertension but may impact HCC visualization.

Subscribe to